STOCK TITAN

Neuropace, Inc. - NPCE STOCK NEWS

Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.

NeuroPace, Inc. is a leading commercial-stage medical device company based in Silicon Valley, focused on transforming the lives of individuals suffering from epilepsy. Founded with the mission to design, develop, manufacture, and market implantable devices for neurological disorders, NeuroPace has made significant strides in the field of responsive neurostimulation.

At the core of NeuroPace's innovation is the RNS® System. This award-winning technology, akin to a pacemaker for the heart, is the world's first and only medical device capable of monitoring and responding to brain activity in real-time. The RNS® System is specifically designed to treat epilepsy, a neurological disorder that affects approximately 1% of the global population, by reducing or eliminating debilitating seizures. The system is primarily used in hospital facilities, particularly Level 4 Comprehensive Epilepsy Centers (CECs).

Beyond epilepsy, the promise of responsive neurostimulation extends to several other disabling medical conditions, potentially improving the quality of life for millions worldwide. NeuroPace is recognized for its patient-centric approach and continuous advancements in the field of neurological treatments.

Recent achievements include the RNS® System being featured in over 50 scientific presentations and posters, underscoring its impact and the ongoing research dedicated to improving its efficacy. The company also maintains significant partnerships and collaborations to further its mission and ensure the RNS® System remains at the forefront of medical innovation.

Financially, NeuroPace derives nearly all its revenue from the sales of the RNS® System, highlighting the product's centrality to the company’s business model. With a strong focus on patient outcomes and continuous technological advancement, NeuroPace is well-positioned to lead in the field of neurological disorder treatments.

Rhea-AI Summary
NeuroPace, Inc. reports Q3 2023 revenue of $16.4 million, a 47% YoY increase. Full-year revenue guidance raised to $62.5-$63.5 million. Cash burn reduced to $2.2 million in Q3 2023. Gross margin improves to 74.5%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
-
Rhea-AI Summary
NeuroPace announces enhancements to its RNS System to streamline care for epilepsy patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
none
-
Rhea-AI Summary
NeuroPace, Inc. will report Q3 2023 financial results on November 6, 2023, after market close. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET. Webcast and telephone access available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
conferences earnings
Rhea-AI Summary
NeuroPace to participate in fireside chat at Cantor Fitzgerald Global Healthcare Conference on September 28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
conferences
-
Rhea-AI Summary
NeuroPace, Inc. to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.28%
Tags
conferences
-
Rhea-AI Summary
NeuroPace reports Q2 2023 revenue of $16.5M, up 62% YoY. Full-year revenue guidance increased to $59-$61M. Cash burn reduced to $4M in Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
conferences earnings
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.21%
Tags
none
Rhea-AI Summary
NeuroPace, a medical device company focused on epilepsy, has appointed Kelley Nicholas as Vice President of Sales. Nicholas brings over 15 years of experience in the medical device industry and has a track record of building high-performing teams and implementing growth-oriented strategies. NeuroPace expects Nicholas to drive the continued growth and success of its sales and commercial program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none

FAQ

What is the current stock price of Neuropace (NPCE)?

The current stock price of Neuropace (NPCE) is $6.335 as of November 4, 2024.

What is the market cap of Neuropace (NPCE)?

The market cap of Neuropace (NPCE) is approximately 182.8M.

What is NeuroPace, Inc. known for?

NeuroPace is known for its innovative RNS® System, the first and only medical device that monitors and responds to brain activity to treat epilepsy.

What medical condition does the RNS® System primarily target?

The RNS® System primarily targets epilepsy, helping to reduce or eliminate debilitating seizures.

Where is NeuroPace, Inc. based?

NeuroPace, Inc. is based in Silicon Valley.

How does the RNS® System work?

Similar to a pacemaker for the heart, the RNS® System monitors brain activity in real-time and responds with electrical stimulation to prevent seizures.

Who are the primary customers for the RNS® System?

The primary customers are hospital facilities, particularly Level 4 Comprehensive Epilepsy Centers (CECs).

What recent achievements has NeuroPace made?

The RNS® System has been featured in over 50 scientific presentations and posters, showcasing its impact and ongoing research.

How does NeuroPace generate revenue?

NeuroPace generates revenue predominantly through the sales of the RNS® System.

Can the RNS® System treat conditions other than epilepsy?

Yes, responsive neurostimulation holds the promise of treating several other disabling medical disorders.

What makes the RNS® System unique?

The RNS® System is the world’s first and only device that can monitor and respond to brain activity in real-time to treat neurological disorders.

Who can be contacted for investor-related inquiries at NeuroPace?

Jeremy Feffer, Managing Director at LifeSci Advisors, can be contacted for investor-related inquiries.

Neuropace, Inc.

Nasdaq:NPCE

NPCE Rankings

NPCE Stock Data

182.77M
29.20M
4.19%
83.53%
1.74%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
MOUNTAIN VIEW